Clinical Trials · NCT05582499
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Fudan University
- Enrollment
- 716
- Start date
- Nov 2022
- Locations
- 1 site, China
- Primary endpoint
- Pathological complete response rate (pCR)